Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
    • Publication Information:
      Publication: 2021- : [New York] : Elsevier
      Original Publication: New York, Grune & Stratton [etc.]
    • Subject Terms:
      Blood Platelets*/physiology ; Blood Preservation*/methods ; Plateletpheresis* ; Solutions*/chemistry; Carbon Dioxide/metabolism ; Cell Survival ; Glucose/metabolism ; Humans ; Hydrogen-Ion Concentration ; Oxygen Consumption ; Plasma/chemistry ; Quality Control ; Time Factors
    • Abstract:
      To evaluate the poststorage viability of apheresis platelets stored for up to 18 days in 80% platelet additive solution (PAS)/20% plasma, 117 healthy subjects donated platelets using the Haemonetics MCS+, COBE Spectra (Spectra), or Trima Accel (Trima) systems. Control platelets from the same subjects were compared with their stored test PAS platelets by radiolabeling their stored and control platelets with either (51)chromium or (111)indium. Trima platelets met Food and Drug Administration poststorage platelet viability criteria for only 7 days vs almost 13 days for Haemonetics platelets; ie, platelet recoveries after these storage times averaged 44 ± 3% vs 49 ± 3% and survivals were 5.4 ± 0.3 vs 4.6 ± 0.3 days, respectively. The differences in storage duration are likely related to both the collection system and the storage bag. The Spectra and Trima platelets were hyperconcentrated during collection, and PAS was added, whereas the Haemonetics platelets were elutriated with PAS, which may have resulted in less collection injury. When Spectra and Trima platelets were stored in Haemonetics' bags, poststorage viability was significantly improved. Platelet viability is better maintained in vitro than in vivo, allowing substantial increases in platelet storage times. However, implementation will require resolution of potential bacterial overgrowth during storage.
    • References:
      Blood. 2009 Apr 9;113(15):3406-17. (PMID: 19188662)
      Transfusion. 1986 Jan-Feb;26(1):30-6. (PMID: 3511573)
      Transfusion. 1992 Jun;32(5):435-40. (PMID: 1626346)
      Transfusion. 1975 Sep-Oct;15(5):414-21. (PMID: 823)
      N Engl J Med. 1994 Sep 8;331(10):625-8. (PMID: 8052271)
      Transfusion. 1998 Jan;38(1):31-40. (PMID: 9482391)
      Vox Sang. 1990;59(3):146-52. (PMID: 2264317)
      Transfusion. 1996 Nov-Dec;36(11-12):1033-4. (PMID: 8937416)
      Transfusion. 2013 May;53(5):972-80. (PMID: 22882530)
      Transfusion. 1986 Jan-Feb;26(1):37-42. (PMID: 3080829)
      Transfusion. 1991 Jan;31(1):21-5. (PMID: 1824731)
      Int J Artif Organs. 1993 Dec;16 Suppl 5:135-8. (PMID: 8013972)
      Transfusion. 2004 Jan;44(1):131-3. (PMID: 14692979)
      Transfusion. 1995 Jan;35(1):50-3. (PMID: 7998070)
      Transfusion. 1989 Sep;29(7):605-9. (PMID: 2773027)
      Vox Sang. 1990;59(1):12-8. (PMID: 2396367)
      Vox Sang. 2003 May;84(4):256-64. (PMID: 12757499)
      Transfusion. 1985 Nov-Dec;25(6):551-6. (PMID: 4071600)
      Vox Sang. 2008 Feb;94(2):103-12. (PMID: 18034786)
      Vox Sang. 2005 Jul;89(1):11-8. (PMID: 15938735)
      Vox Sang. 1994;66(1):18-24. (PMID: 8146978)
      Vox Sang. 1987;52(4):305-12. (PMID: 3630056)
      Transfusion. 2001 Jul;41(7):917-22. (PMID: 11452160)
      Transfusion. 2011 Jun;51(6):1241-8. (PMID: 21214584)
      Vox Sang. 2003 Nov;85(4):267-75. (PMID: 14633252)
      J Clin Apher. 2006 Jul;21(2):142-51. (PMID: 15880369)
      Vox Sang. 2006 Feb;90(2):92-6. (PMID: 16430666)
      Blood. 1986 Mar;67(3):672-5. (PMID: 3947742)
      Blood. 1988 Feb;71(2):448-52. (PMID: 3337906)
      Vox Sang. 1987;53(4):214-20. (PMID: 3125686)
      Vox Sang. 2004 Apr;86(3):183-8. (PMID: 15078253)
      Transfus Med. 1993 Jun;3(2):103-13. (PMID: 8374698)
      Vox Sang. 2013 May;104(4):324-30. (PMID: 23384253)
      Comput Biol Med. 1988;18(4):305-15. (PMID: 3409677)
      Br J Haematol. 1987 Jun;66(2):233-8. (PMID: 3606958)
      Transfusion. 1991 Jan;31(1):16-20. (PMID: 1986461)
      Vox Sang. 1987;53(4):199-202. (PMID: 3439098)
      Vox Sang. 2007 Jan;92(1):32-6. (PMID: 17181588)
      Blood. 1995 Nov 15;86(10):3951-60. (PMID: 7579366)
      Transfusion. 1997 May;37(5):476-81. (PMID: 9149770)
    • Grant Information:
      P50 HL081015 United States HL NHLBI NIH HHS
    • Accession Number:
      0 (Solutions)
      142M471B3J (Carbon Dioxide)
      IY9XDZ35W2 (Glucose)
    • Publication Date:
      Date Created: 20131122 Date Completed: 20140306 Latest Revision: 20211021
    • Publication Date:
      20231215
    • Accession Number:
      PMC3888291
    • Accession Number:
      10.1182/blood-2013-05-501247
    • Accession Number:
      24258816